Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. They are focused on developing new medicines to treat patients with respiratory diseases such as cystic fibrosis, asthma, and COPD, aiming to improve patient quality of life and reduce the frequency of lung infections.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.

In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life. 

The leadership team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. The company benefits from a close working relationship with the School of Life Sciences at the University of Sussex.

Cystic Fibrosis Foundation

Cystic Fibrosis Trust

Imperial Innovations

IP Group

Epidarex Capital

Forbion Capital Partners

Novartis Venture Fund

Versant Ventures

Enterprise Therapeutics

#CysticFibrosis affects over 10,800 people in the UK, with one in 25 of us carrying the #gene #mutation that causes it, often without knowing.

Join us for #CFWeek to raise awareness and celebrate the #innovative progress that the #scientific community has already made in #CF #research, #drugdiscovery and #drugdevelopment, as well as the exciting breakthroughs on the horizon.

You can get involved with Cystic Fibrosis Trust here: https://rb.gy/li8ux 
#CysticFibrosisAwareness

What is the importance of endpoints in #raredisease #research?
 
In conversation with International Clinical Trials (Samedan Ltd), our CMO, Dr Niyati Prasad shares her insight on conducting #clinicaltrials for rare diseases, from how #researchers can best select primary and secondary endpoints to the role of ePROs.
 
Read the full interview here: https://bit.ly/3C6hZ0p

Every May, the #cysticfibrosis community comes together for #CFAwarenessMonth, with the unified aim to raise #disease awareness and find a cure for all people with #CF.

Joining this mission, Enterprise Therapeutics is dedicated to the #research, development, and delivery of novel muco-regulatory treatments for CF and other #respiratorydiseases. 

Learn more about our approach here: https://bit.ly/3o6E2An

Our Chief #Medical Officer, Dr Niyati Prasad, is presenting at #Clinical #Outsourcing Group UK.
 
Join Niyati to hear key insights on identifying accurate endpoints to improve clinical study design for #rarediseases.
 
Learn more and register here: https://bit.ly/3X0Wh6P #COGUK

COM:ENTERPRISETHERAPEUTICS

Enterprise Therapeutics

Analysis Not Available